Menu
Menu
Kate Bligh is a highly experienced communications consultant, facilitator, trainer, and certified life coach (Website: katebligh.com). She holds an MFA degree in theatre directing and is a part-time professor in the Departments of Applied Human Sciences, Education, Theatre, English, and Irish Studies at Concordia University in Montreal.
Kate has been providing both coaching and training, across a wide spectrum of communications skills, to residents and surgeons at the McGill University Health Centre since 2011. She is also a thriving and grateful former surgical patient at the Montreal General Hospital.
Dr. Boorjian is the Carl Rosen Professor of Urology and the David and Anne Luther Chair of the Department of Urology at Mayo Clinic. He also serves as the Program Director for Mayo’s Urologic Oncology Fellowship.
He received his MD from Harvard Medical School and was a resident in urology at New York Presbyterian Hospital-Weill Cornell Medical Center. He subsequently completed a fellowship in urologic oncology at Mayo Clinic.
Dr. Boorjian has co-authored over 500 manuscripts and book chapters and was recognized as “Teacher of the Year” in urology for 2012 by the Mayo Clinic Fellows’ Association. He received the Young Urologist of the Year award from the AUA in 2014 and 2018, as well as the 2016 Young Investigator Award from the Society of Urologic Oncology. He was a previous member of the NCCN Guidelines Panels for Bladder Cancer and Penile Cancer, has served as a member of the AUA Non-Muscle Invasive Bladder Cancer Guideline Panel, as co-chair of the AUA Microhematuria Guideline Panel, and as Vice-Chair of the Clinically Localized Prostate Cancer Guideline Panel. He is a former Associate Editor of European Urology.
Clinically, his practice includes a breadth of urologic oncology, including bladder cancer, kidney cancer (in particular, locally advanced tumors with tumor thrombus), prostate cancer, testicular cancer, and penile cancer.
Dr. Brucker is a Professor of Urology and Obstetrics and Gynecology at New York University Langone Health in New York City. He is the Director of the Division of Urogynecology and Reconstructive Pelvic Surgery and Neuro-urology. Dr. Brucker also serves as the department’s safety officer and is the Program Director of the urogynecology and reconstructive surgery fellowship.
He earned his medical degree from the University of Pennsylvania School of Medicine and completed his postgraduate medical training at the Hospital of the University of Pennsylvania and then at New York University.
Dr. Brucker has an interest in male and female incontinence and pelvic floor disorders. He has authored numerous papers and lectured internationally on these topics. He has a research interest in urodynamics, neuro-urology, and overactive bladder.
He is a past recipient of the prestigious SUFU McGuire-Zimskind Award, given to one outstanding member each year for their contribution and leadership. He was a founding member of the Young SUFU Members Committee and the SUFU Research Network. He currently sits on the board of SUFU and is also a member of the AUA, SUFU, ICS, and AUGS.
Dr. Efstathiou is a Professor of Radiation Oncology at Harvard Medical School (HMS), Vice-Chair for Faculty & Academic Affairs and Director of the Genitourinary (GU) Division in the Department of Radiation Oncology, and Clinical Co-Director of The Claire and John Bertucci Center for GU Cancers at the Massachusetts General Hospital/Mass General Brigham.
Dr. Efstathiou holds a BS from Yale University, MD from HMS, DPhil from the University of Oxford, and completed his residency training in the Harvard Radiation Oncology Program.
He is an internationally recognized leader in GU malignancies and radiation oncology. His research has informed clinical guidelines and made novel contributions to organ-preservation therapy for bladder cancer, advanced radiation technologies for prostate cancer, as well as global oncology outreach efforts.
He is the recipient of significant grant funding and serves as the principal investigator (PI) or co-chair of multiple multicenter, NCI-sponsored, randomized trials in prostate and bladder cancer, including PI of the PARTIQoL RCT of protons vs. photons for localized prostate cancer and co-PI of the SWOG/NRG 1806 RCT of chemoRT ± atezolizumab for muscle-invasive bladder cancer.
Dr. Efstathiou holds multiple leadership and board positions within professional societies (ASTRO, ASCO, ABR, ACRO, ROI) including serving as Past-Chair of the Genitourinary Cancers Symposium (GU-ASCO); within the NCI, where he previously served as Co-Chair of the Bladder Cancer Task Force and currently serves as Co-Chair of the GU Steering Committee; within NRG Oncology, where he serves as the Vice-Chair of the GU Steering Committee and Bladder Lead; and within patient advocacy organizations (BCAN, MPCC). In addition, he has a strong proven track record in teaching and mentorship and was awarded the A. Clifford Barger Excellence in Mentoring Award from HMS.
Dr. Eisner is an endourologist at Massachusetts General Hospital, Harvard Medical School. He is an Associate Professor of Surgery (Harvard Medical School), Director of the MGH Kidney Stone Program, and the Chief of Urology at Newton Wellesley Hospital.
He is a graduate of Harvard University and the University of Michigan Medical School. He completed his urology residency at Harvard (Massachusetts General Hospital), and an endourology and stone disease fellowship at the University of California, San Francisco.
Dr. Eisner’s practice focuses on the evaluation, medical management, and surgical treatment of patients with urolithiasis, as well as endourologic management of benign and malignant disease. His research interests include surgical and medical management of stone disease, risk factors for stone formation, and risk factors and treatment for infection in patients with stone disease.
Dr. Gospodarowicz is a Professor of Radiation Oncology at the University of Toronto and Past Director of the Princess Margaret Cancer Centre. She has had a long-standing interest in clinical research in genitourinary cancers, lymphomas, and cancer staging. Her current interests include global cancer control, global access to radiotherapy, and technology innovation.
She is the past-president of UICC and has been involved in the Lancet Oncology Commissions on expanding the global access to radiotherapy. She currently co-Chairs the Lancet Commission on Cancer and Health Systems and the Lancet Oncology Commission on Cancer in the Commonwealth.
Dr. Greenwell was appointed as a Consultant Urological Surgeon at University College London Hospital (UCLH) in 2002 and has led the 7 Consultant Female, Functional, Reconstructive and Adolescent Urology Unit since 2011. She has been: Postgraduate Tutor in Urology for University College London (UCL), Royal College of Surgeons of England (RCS Eng) Raven Tutor in Urology, the British Association of Urological Surgeons (BAUS) Director of Education, a member of the Intercollegiate Urology SAC (Speciality Advisory Committee), Chair of the Functional, Neuro-Urology and Urodynamics (FNUU) section of BAUS, and a member of the Board of Directors of the AUA Genitourinary Reconstructive Surgeons (GURS) Section. She is currently President of the United Kingdom Continence Society, an examiner for the FRCS (Urol), a member of the EAU Genitourinary Reconstruction Section, the EAU Video-congress Committee, a member of the EAU Urethral Stricture Guidelines Committee, and a faculty member of EUREP.
Her clinical practice is in complex male and female urinary incontinence, male and female urethral stricture, female urethral diverticulum, lower urinary tract reconstruction, urinary tract fistulae, and ureteric injury. She continues to have a significant interest in surgical education — in particular skills acquisition. She has over 150 peer-reviewed publications and book chapters.
Dr. Lee is an Associate Professor at the University of Toronto. He also serves as the Program Director for the residency training program and is part of the University of Toronto’s Endourological Society fellowship. In addition, he is the Surgical Lead – Robotic Surgery Academy at the Temerty Advanced Surgical Education & Simulation Centre.
After completing medical school and residency training at the University of Toronto, Dr. Lee went on to complete a combined clinical and research fellowship in minimally invasive surgery and surgical education at the University of California Irvine. He also obtained master’s degree in health professions education from the University of Illinois at Chicago
Dr. Lee’s clinical practice focuses primarily on robotic surgery, endourology, and kidney transplantation. In addition, his research interests include curriculum development, surgical skills assessment, and the use of simulation-based training in surgical education.
Dr. North is a Professor of Urology and Chief of Pediatric Urology at Montefiore Health Systems. She is the current Chair of the American Urological Association Data Committee and the immediate past-Chair of the AUA Work Force Work Group. She was recently elected to the Executive Board of Directors of the New York Section of the AUA and is a graduate of the AUA Leadership Program. She was Chair-Elect of the Pediatric Health Council of the Urology Care Foundation. She also serves as the New York Section Representative to the American Association of Clinical Urologists and was the former Treasurer of UROPAC. Her research has focused on workforce issues in urology, including burnout and wellness, gender equity, and student loan debt.
Prof. Stenzl is a German urologist and uro-oncologist. He was the Director of the Department of Urology at the Eberhard-Karls-University in Tübingen/Germany and is currently Senior Professor and consultant surgeon at the Diakonissen Hospital in Stuttgart.
His main research interests are bladder and prostate cancer, as well as reconstructive urology. His ongoing research focuses on intraoperative multisensory tissue differentiation in oncology, which is funded by the German Research Foundation.
He has served as President of the German Society of Urology (DGU) and Chair of the Scientific Program Committee of the European Association of Urology (EAU). Since 2019, he has been the EAU Adjunct Secretary General Science and in 2023, he became Secretary General of the EAU.
Prof. Stenzl has written or contributed to more than 840 publications and was a Section Editor for European Urology, a member of the Executive Board of BJU International, and on the editorial board of several other peer-reviewed journals. He has received countless awards, including the Maximillian Nitze Medal, the highest scientific award from the DGU, and the Lifetime Achievement Award at the World Congress of Urologic Oncology.
Dr. Tanaka is a Professor and Chief of Pediatric Urology at the University of Alabama at Birmingham/Children’s of Alabama. Her research interests include neuropathic and non-neuropathic bladder dysfunction. She is the Scientific Vice-Chair for the CDC Spina Bifida Urologic Protocol for Infants and Children and is on the board of the International Children’s Continence Society. She is the editor of the AUANews, the official news magazine of the American Urological Association. She has also previously served on the American Board of Urology examination committee and as an Assistant Editor for the pediatric section of the Journal of Urology.
Dr. Taneja is the James M. and Janet Riha Neissa Professor of Urologic Oncology; Professor of Urology, Radiology, and Biomedical Engineering; GU Program Leader in the Perlmutter Cancer Center; Director of the Division of Urologic Oncology; and Vice-Chair in the Department of Urology at NYU Langone Health.
He received his medical degree from Northwestern University and completed his urology residency at UCLA.
Dr. Taneja is a renowned key opinion leader in the treatment and research of prostate cancer. His previous laboratory research focused on androgen receptor transcriptional activation and the relationship of AR to prostate cancer growth. Over the past 15 years, his clinical research interest has been in prostate cancer diagnostics, with particular focus on the application of imaging in the detection, risk stratification, and therapy of prostate cancer. He has pioneered the clinical application of pre-biopsy prostate MRI and techniques of MRI-targeted biopsy and is widely recognized as an innovator in the emerging field of prostate cancer focal therapy. In 2023, he received the American Urological Association Distinguished Contribution Award for ‘creative and notable contributions in prostate cancer imaging, biopsy, and treatment’.
Dr. Yafi is an Associate Professor of Urology, Chief of the Division Men’s Health and
Reconstructive Urology, Director of Men’s Health and Newport Urology, and Vice-Chair of the
Department of Urology at the University of California, Irvine (UCI). His practice is specialized in
men’s health, erectile dysfunction, hypogonadism, Peyronie’s disease, prosthetic surgery and
male voiding dysfunction/enlarged prostate.
After earning his medical degree from the American University of Beirut, Dr. Yafi completed his
internship in general surgery at the Mayo Clinic in Rochester, MN, and subsequently completed
his residency in urology at McGill University in Montreal, QC. He then completed a two-year
fellowship in andrology, sexual medicine and prosthetic urology at Tulane University.
Dr. Yafi has served on numerous national and international society committees, such as the
Sexual Medicine Society of North America, the International Society for Sexual Medicine, and
the Société Internationale d’Urologie. Notably, he is the Secretary of the Sexual Medicine
Society of North America.
Dr. Yafi has an avid interest in both basic and clinical research. He has contributed more than
250 peer-reviewed publications, educational guidelines, and book chapters, and has received
multiple national and international awards and recognitions, including the UCI Excellence in
Teaching award in 2020, the UCI Rising Stars award in 2020, the Sexual Medicine Society of
North America Young Investigator Award of Excellence in 2022, and the International Society of
Sexual Medicine Rising Star Award in 2024.
Contact
486 Chemin Bord du Lac
Dorval, Quebec H9S 2A8
corporate.office@cua.org